TrialJournal of diabetes investigation2025

Long-term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52-week postmarketing clinical study (TWINKLE).

Tetsuya Babazono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.